DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for dilated cardiomyopathy 1FF — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDilated cardiomyopathy 1FF maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dilated cardiomyopathy 1ff is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1994 follow-up study of 235 patients aged 16 to 70 with dilated cardiomyopathy, enrolled from 1978 to 1992, reported that two-year and four-year survival improved across three consecutive five-year periods. In the earliest period (1978–1982, 26 patients) two-year survival was 73.8% and four-year survival 53.8%. In the middle period (1983–1987, 65 patients) these figures rose to 87.7% and 72.3%. In the most recent period (1988–1992, 144 patients) they reached 90.3% and 82.9%. The authors noted that patients in later periods were younger and less severely affected at enrolment, which partly explained the improvement, but the survival curves diverged progressively and the improvement remained significant after stratification for disease severity, suggesting a sustained effect of treatment. A progressively higher proportion of patients received ACE inhibitors and later beta blockers. In the middle period, patients treated with ACE inhibitors showed better survival than those not treated, after stratification for heart failure severity. In the most recent period, beta blockers had a significant additive effect: four-year survival in patients with mild heart failure treated with beta blockers (plus digitalis and ACE inhibitors) was 90%, and in those with moderate to severe heart failure it was 87.5%.
A 2016 review stated that dilated cardiomyopathy is characterised by ventricular dilation and progressive systolic dysfunction, and that causative genetic mutations have been identified in more than 40 genes encoding proteins from different cellular structures and pathways. The review described the major genes and the pathophysiologic mechanisms, but provided no new clinical trial data.
A 2025 literature review on traditional Chinese medicine for dilated cardiomyopathy stated that conservative drug therapy is mainly used in clinical practice but that adverse reactions such as low blood pressure often make satisfactory prognosis difficult to achieve. It claimed that traditional Chinese medicine has the characteristics of syndrome differentiation and multi-target treatment, with few adverse reactions and certain advantages, and that it has achieved good therapeutic effects in clinical practice. However, the review provided no concrete numbers on survival, response rates, or sample sizes from any trial, and did not name any specific traditional Chinese medicine drug or formulation.
What is still missing is a modern randomised controlled trial that tests a specific repurposed drug against placebo or standard care in a well-characterised, genetically stratified cohort of dilated cardiomyopathy patients, with adequate funding to follow patients for hard endpoints such as death or transplantation. The 1994 data are now three decades old and reflect a different era of background therapy. No abstract provides evidence for any single drug that can be recommended for repurposing today.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Heart · 1994 · 76 citations · open access
Changing mortality in dilated cardiomyopathy
AbstractOBJECTIVE: To analyse the changes in mortality in dilated cardiomyopathy over the past 15 years and to identify the factors that might have influenced survival. DESIGN: Follow up study of 235 patients (aged 16-70) systematically enrolled on a register from 1 January 1978 to 31 December 1992. SETTING: Hospital department of cardiology. PATIENTS: Three groups corresponding to three periods of 5 years: group 1 (diagnosis between 1 January 1978 and 31 December 1982) 26 patients; group 2 (diagnosis between 1 January 1983 and 31 December 1987) 65 patients; and group 3 (diagnosis between 1 January 1988 and 31 December 1992) 144 patients. MAIN OUTCOME MEASURES: Death or heart transplantation. RESULTS: Two and four year survival was 73.8% and 53.8% in group 1, 87.7% and 72.3% in group 2, and 90.3% and 82.9% in group 3 (P = 0.02). During the 15 years of the study period the number of cases increased progressively and the baseline clinical characteristics changed (that is, patients were younger and less severely affected), partly explaining the improvement in survival. None the less, the three mortality curves tended to diverge progressively and the improvement in survival in the different groups was still significant after stratification for the severity of the disease, suggesting that treatment had a sustained effect. A progressively higher proportion of patients were treated with angiotensin converting enzyme (ACE) inhibitors and more recently with beta blockers. In group 2, after stratification for the severity of heart failure, patients who were treated with ACE inhibitors showed a better survival than patients who were not. Furthermore, analysis of group 3 showed that beta blockers had a significant additive effect with conventional therapy both by intention to treat and actual treatment. Four year survival in patients with mild and moderate to severe heart failure treated with beta blockers, and usually digitalis and ACE inhibitors, was respectively 90% and 87.5%. CONCLUSIONS: The improvement in the survival of patients with dilated cardiomyopathy over the past 15 years may be explained by earlier diagnosis, new treatments, and a change in the clinical characteristics of the patients at enrolment.
Journal of Cardiovascular Medicine · 2016 · 15 citations
Genetic bases of dilated cardiomyopathy
AbstractCardiomyopathies represent a wide and heterogeneous group of diseases wherein a genetic cause has been consistently identified.Dilated cardiomyopathy (DCM) is characterized by ventricular dilation and progressive systolic dysfunction, and it is the most common form of cardiomyopathy.Causative genetic mutations have been identified in more than 40 genes encoding proteins belonging to different cellular structures and pathways.A great diversity of pathways has been implied in the pathogenesis of DCM, depending on the affected genes and on the dislodged intracellular structures or mechanisms.This review describes the major genes and focus on the pathophysiologic mechanisms of DCM, with a special consideration of the most recent discoveries in the field.
Current Opinion in Cardiology · 1991 · 1 citations
Dilated cardiomyopathy
AbstractDilated cardiomyopathy is the most common form of cardiomyopathy and is anatomically defined by large atrial and ventricular chambers, thin or normal myocardial walls, and poor systolic function. In the United States, up to 10,000 deaths every year have been determined to be secondary to cardiomyopathy, and of these 80% were due to the dilated form of the disease. This review describes recent advances of DCM, which can be grouped into the following headings: 1)etiologies and mechanisms of disease; 2) pathophysiology of the dilated heart; 3) diagnostic approaches; 4) clinical findings and prognosis; and 5) therapy.
International Journal of General Medicine · 2025 · 0 citations · open access
Traditional Chinese Medicine Treating Dilated Cardiomyopathy: A Literature Review
AbstractDilated cardiomyopathy (DCM), as a difficult problem in modern medical treatment, has become an important cardiovascular disease threatening human beings all over the world with an increasing incidence rate and mortality. Conservative drug therapy is mainly used in clinical practice, but due to unavoidable adverse reactions such as low blood pressure, it is often difficult to achieve satisfactory prognosis. Traditional Chinese medicine has the characteristics of syndrome differentiation and multi-target treatment for DCM, with few adverse reactions and certain advantages. It has achieved good therapeutic effects in clinical practice. Therefore, we summarized and analyzed the clinical evidence and mechanism of traditional Chinese medicine in the treatment of DCM, and combined with the current research status of this disease to analyze the problems and shortcomings, in order to provide more ideas and methods for the treatment of DCM with traditional Chinese medicine.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
